Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases

被引:127
作者
Woodard, CL
Li, ZY
Kathcart, AK
Terrell, J
Gerena, L
Lopez-Sanchez, M
Kyle, DE
Bhattacharjee, AK
Nichols, DA
Ellis, W
Prigge, ST
Geyer, JA
Waters, NC [1 ]
机构
[1] Walter Reed Army Inst Res, Div Expt Therapeut, Silver Spring, MD 20910 USA
[2] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Malaria Res Inst, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA
[3] USA, Med Res Unit Kenya 64109, APO, AE 09831 USA
关键词
D O I
10.1021/jm0300983
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cyclin dependent protein kinases (CDKs) have become attractive drug targets in an effort to identify effective inhibitors of the parasite Plasmodium falciparum, the causative agent of the most severe form of human malaria. We tested known CDK inhibitors for their ability to inhibit two malarial CDKs: Pfmrk and PfPK5. Many broad spectrum CDK inhibitors failed to inhibit Pfmrk suggesting that the active site differs from other CDKs in important ways. By screening compounds in the Walter Reed chemical database, we identified oxindole-based compounds as effective inhibitors of Pfmrk (IC50 = 1.5 muM). These compounds have low cross-reactivity against PfPK5 and human CDK1 demonstrating selectivity for Pfmrk. Amino acid comparison of the active sites of Pfmrk and PfPK5 identified unique amino acid differences that may explain this selectivity and be exploited for further drug development efforts.
引用
收藏
页码:3877 / 3882
页数:6
相关论文
共 42 条
[1]   The Plasmodium cell-cycle: facts and questions [J].
Arnot, DE ;
Gull, K .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1998, 92 (04) :361-365
[2]   Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles [J].
Arris, CE ;
Boyle, FT ;
Calvert, AH ;
Curtin, NJ ;
Endicott, JA ;
Garman, EF ;
Gibson, AE ;
Golding, BT ;
Grant, S ;
Griffin, RJ ;
Jewsbury, P ;
Johnson, LN ;
Lawrie, AM ;
Newell, DR ;
Noble, MEM ;
Sausville, EA ;
Schultz, R ;
Yu, W .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (15) :2797-2804
[3]   Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases [J].
Barvian, M ;
Boschelli, DH ;
Cossrow, J ;
Dobrusin, E ;
Fattaey, A ;
Fritsch, A ;
Fry, D ;
Harvey, P ;
Keller, P ;
Garrett, M ;
La, F ;
Leopold, W ;
McNamara, D ;
Quin, M ;
Trumpp-Kallmeyer, S ;
Toogood, P ;
Wu, ZP ;
Zhang, EL .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (24) :4606-4616
[4]   Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis [J].
Bramson, HN ;
Corona, J ;
Davis, ST ;
Dickerson, SH ;
Edelstein, M ;
Frye, SV ;
Gampe, RT ;
Harris, PA ;
Hassell, A ;
Holmes, WD ;
Hunter, RN ;
Lackey, KE ;
Lovejoy, B ;
Luzzio, MJ ;
Montana, V ;
Rocque, WJ ;
Rusnak, D ;
Shewchuk, L ;
Veal, JM ;
Walker, DH ;
Kuyper, LF .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (25) :4339-4358
[5]   RETRACTED: Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors (Retracted Article. See vol 298, pg 2327, 2002) [J].
Davis, ST ;
Benson, BG ;
Bramson, HN ;
Chapman, DE ;
Dickerson, SH ;
Dold, KM ;
Eberwein, DJ ;
Edelstein, M ;
Frye, SV ;
Gampe, RT ;
Griffin, RJ ;
Harris, PA ;
Hassell, AM ;
Holmes, WD ;
Hunter, RN ;
Knick, VB ;
Lackey, K ;
Lovejoy, B ;
Luzzio, MJ ;
Murray, D ;
Parker, P ;
Rocque, WJ ;
Shewchuk, L ;
Veal, JM ;
Walker, DH ;
Kuyper, LF .
SCIENCE, 2001, 291 (5501) :134-137
[6]   QUANTITATIVE ASSESSMENT OF ANTI-MALARIAL ACTIVITY INVITRO BY A SEMIAUTOMATED MICRODILUTION TECHNIQUE [J].
DESJARDINS, RE ;
CANFIELD, CJ ;
HAYNES, JD ;
CHULAY, JD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1979, 16 (06) :710-718
[7]  
Doerig C, 2000, Prog Cell Cycle Res, V4, P163
[8]   Cyclin-dependent kinase homologues of Plasmodium falciparum [J].
Doerig, C ;
Endicott, J ;
Chakrabarti, D .
INTERNATIONAL JOURNAL FOR PARASITOLOGY, 2002, 32 (13) :1575-1585
[9]   Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics [J].
Fischer, PM ;
Lane, DP .
CURRENT MEDICINAL CHEMISTRY, 2000, 7 (12) :1213-1245
[10]  
Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO